drugset / Trial / NCT00237523

Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain

NCT00237523 ↗

Phase 3 Unknown 175 enrolled Symbollon Pharmaceuticals
RandomizedSingle-groupDouble-blindTreatment

Summary

* History of clinical breast pain for at least the last six months. * At least six days of moderate or severe breast pain per cycle. * Fibrosis, cysts, nodules involving at least 25% of the surface of one breast. * Euthyroid with no prior history of thyroid disease. * Six months of daily therapy with molecular iodine. * Placebo controlled vs active (1:1).

Timeline

Start
2005-07
Primary completion
—
Completion
2008-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject molecular iodine Unknown — —